Oncternal Therapeutics Inc (ONCT) Stock Overview
USA - NASDAQ:ONCT - US68236P2065 - Common Stock
ONCT Key Statistics, Chart & Performance
The current stock price of ONCT is 0.5266 USD. In the past month the price decreased by -64.89%. In the past year, price decreased by -93.89%.
ONCT Latest News, Press Relases and Analysis
ONCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 14.46 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 345.82 | 58.93B | ||
| ARGX | ARGENX SE - ADR | 61.91 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.97 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 8.94 | 21.93B |
Related stock screener links
About ONCT
Company Profile
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Company Info
Oncternal Therapeutics Inc
12230 El Camino Real, Suite 230
San Diego CALIFORNIA 92130 US
CEO: James B. Breitmeyer
Employees: 27
Phone: 18584341113
Oncternal Therapeutics Inc / ONCT FAQ
What does Oncternal Therapeutics Inc do?
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
What is the stock price of Oncternal Therapeutics Inc today?
The current stock price of ONCT is 0.5266 USD. The price decreased by -24.11% in the last trading session.
Does Oncternal Therapeutics Inc pay dividends?
ONCT does not pay a dividend.
How is the ChartMill rating for Oncternal Therapeutics Inc?
ONCT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for ONCT stock?
Oncternal Therapeutics Inc (ONCT) currently has 27 employees.
What is the market capitalization of ONCT stock?
Oncternal Therapeutics Inc (ONCT) has a market capitalization of 1.56M USD. This makes ONCT a Nano Cap stock.
ONCT Technical Analysis
ONCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONCT. While ONCT seems to be doing ok healthwise, there are quite some concerns on its profitability.
ONCT Financial Highlights
Over the last trailing twelve months ONCT reported a non-GAAP Earnings per Share(EPS) of -11.69. The EPS increased by 18.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.62% | ||
| ROE | -377.95% | ||
| Debt/Equity | 0 |
ONCT Forecast & Estimates
6 analysts have analysed ONCT and the average price target is 2.04 USD. This implies a price increase of 287.39% is expected in the next year compared to the current price of 0.5266.
For the next year, analysts expect an EPS growth of 10.27% and a revenue growth 161.75% for ONCT